

Notice of results

London, 26 February 2019 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) will announce its preliminary financial results for the year ended 31 December 2018 on Wednesday 13 March 2019.

A presentation and webcast for analysts will be held at 9.30am GMT at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.

To join via conference call please dial:
UK toll free number: 020 3936 2999
US toll free number: 1 845 709 8568
Standard international access: +44 20 3936 2999
Password: 078263

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or <http://webcast.openbriefing.com/hikmaPR2018/>.

Playback facility:

A playback of the conference call will be available up to 3 months after the presentation.

UK number: 020 3936 3001
International number: +44 20 3936 3001
Replay PIN code: 685891

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050
EVP, Strategic Planning and Global Affairs

Lucinda Baker +44 (0)20 7399 2765/ +44 7818 060211
Deputy Director of Investor Relations

Virginia Spring +44 (0)20 3892 4389/ +44 7973 679502
Senior Investor Relations Manager

FTI Consulting

Ben Atwell/Andrew Ward +44 (0)20 3727 1000



About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.